Stage <scp>III</scp> substaging and outcomes in patients with bladder cancer undergoing radical cystectomy
Shuhei Hara(Jikei University School of Medicine), Taketo Kawai(National Center for Global Health and Medicine), Sho Sekito(Aichi Cancer Center), Tomokazu Sazuka(Chiba University), Fumihiko Urabe(Jikei University School of Medicine), Keiji Yasue(Higashi Nagoya National Hospital), Wataru Fukuokaya(Jikei University School of Medicine), Yoshiyuki Matsui(Tokyo National Hospital), Shuichi Tatarano(Kagoshima University), Jun Miki(Jikei University School of Medicine), Katsuyoshi Hashine(Shikoku Cancer Center), Takeshi Sano(Tokushima University), Kenichiro Shiga(Harasanshin Hospital), Yusuke Sugino(Mie University), Rikiya Taoka(Kagawa University), Takuji Hayashi(Osaka International Cancer Institute), Koichiro Wada(Shimane University), Junichi Inokuchi(Kyushu University), Hiroaki Matsumoto(Yamaguchi University), Soki Kashima(Akita University), Makito Miyake(Nara Medical University), Kiyoaki Nishihara(Kurume University), Yuto Matsushita(Hamamatsu University School of Medicine), Yoji Murakami(Kumamoto University), Ryoichi Saito(University of Miyazaki), Hirohito Naito(Kagawa University), Noriya Yamaguchi(Tottori University), Hiroyuki Nishiyama(University of Tsukuba), Shotaro Nakanishi(University of the Ryukyus), Kei Daizumoto(Tokushima University), Takashige Abe(Hokkaido University), Takahiro Kimura(Jikei University School of Medicine), Ayumu Matsuda(Tokyo National Hospital), Shingo Yamamoto(Hyogo University), Minoru Kato(Osaka International Cancer Institute), Takashi Kawahara(University of Tsukuba), Hiroshi Kitamura(University of Toyama), Shingo Hatakeyama(Hirosaki University), Masato Fujii(Niigata University), Naotaka Nishiyama(University of Toyama), Ryo Maruyama(Niigata University)
Cited by 7
Related Papers
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388